Propranolol with pembrolizumab and chemotherapy for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding propranolol (a common blood-pressure/heart medicine) can improve outcomes when used with pembrolizumab plus standard chemotherapy. It is for people with advanced esophageal or gastroesophageal junction adenocarcinoma that cannot be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is newly diagnosed and cannot be removed by surgery or has spread, and you have not had standard cancer drugs for it (with limited exceptions).
- Your general condition is good (ECOG performance status 0 to 1).
- You can provide tumor tissue from a biopsy done within the last year, or you agree to a new biopsy before treatment starts.
- Your lab tests meet minimum safety levels (blood counts, kidney function, and liver/bilirubin levels).
- You can take propranolol by mouth (or by liquid through a feeding tube if swallowing is hard).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding propranolol (a common blood-pressure/heart medication) to standard chemotherapy and radiation can improve outcomes for people with esophageal adenocarcinoma. You would start propranolol around the time of treatment, with careful heart monitoring and study follow-up.
This trial tests adding a blood pressure medicine (propranolol) to standard chemotherapy and immunotherapy before surgery for locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This Phase 2 trial studies whether adding propranolol to pembrolizumab can “re-sensitize” tumors and slow cancer in triple-negative breast cancer that no longer responds to checkpoint immunotherapy. It may help some people whose cancer has grown despite prior pembrolizumab and chemotherapy.
This Phase 2 trial tests whether combining propranolol (a blood-pressure/heart medicine) with pembrolizumab (an immune therapy) can help people with advanced angiosarcoma or undifferentiated pleomorphic sarcoma that has progressed after first-line chemotherapy. It aims to slow tumor growth and improve outcomes while also studying tumor markers from your biopsy tissue.
This trial tests adding a beta-blocker (propranolol) to a combination of immunotherapy (sintilimab) and standard chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this new triple treatment helps shrink tumors better than chemo-immunotherapy alone.
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
Hear when a new Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.